147 related articles for article (PubMed ID: 7947604)
1. Selective inhibition of platelet macroaggregate formation by a recombinant heparin-binding domain of human thrombospondin.
Legrand C; Morandi V; Mendelovitz S; Shaked H; Hartman JR; Panet A
Arterioscler Thromb; 1994 Nov; 14(11):1784-91. PubMed ID: 7947604
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin peptides inhibit the secretion-dependent phase of platelet aggregation.
Rabhi-Sabile S; Thibert V; Legrand C
Blood Coagul Fibrinolysis; 1996 Mar; 7(2):237-40. PubMed ID: 8735828
[TBL] [Abstract][Full Text] [Related]
3. Molecular requirements for the interaction of thrombospondin with thrombin-activated human platelets: modulation of platelet aggregation.
Legrand C; Thibert V; Dubernard V; Bégault B; Lawler J
Blood; 1992 Apr; 79(8):1995-2003. PubMed ID: 1562725
[TBL] [Abstract][Full Text] [Related]
4. A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan.
Ferrari do Outeiro-Bernstein MA; Nunes SS; Andrade AC; Alves TR; Legrand C; Morandi V
Matrix Biol; 2002 Jun; 21(4):311-24. PubMed ID: 12128069
[TBL] [Abstract][Full Text] [Related]
5. A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor.
Bonnefoy A; Hantgan R; Legrand C; Frojmovic MM
J Biol Chem; 2001 Feb; 276(8):5605-12. PubMed ID: 11094060
[TBL] [Abstract][Full Text] [Related]
6. Role of thrombospondin in platelet aggregation.
Leung LL
J Clin Invest; 1984 Nov; 74(5):1764-72. PubMed ID: 6501568
[TBL] [Abstract][Full Text] [Related]
7. Proteolysis of thrombospondin during cathepsin-G-induced platelet aggregation: functional role of the 165-kDa carboxy-terminal fragment.
Rabhi-Sabile S; Pidard D; Lawler J; Renesto P; Chignard M; Legrand C
FEBS Lett; 1996 May; 386(1):82-6. PubMed ID: 8635609
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel monoclonal antibody (V58A4) raised against a recombinant NH2-terminal heparin-binding fragment of human endothelial cell thrombospondin.
Morandi V; Edelman L; Legrand YJ; Legrand C
FEBS Lett; 1994 Jun; 346(2-3):156-60. PubMed ID: 8013625
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin as an agglutinin of platelets.
Satoh S; Takahashi K; Sakuragawa N
Thromb Res; 1993 Dec; 72(6):509-17. PubMed ID: 8128455
[TBL] [Abstract][Full Text] [Related]
10. Osteonectin is an alpha-granule component involved with thrombospondin in platelet aggregation.
Clezardin P; Malaval L; Morel MC; Guichard J; Lecompte T; Trzeciak MC; Dechavanne M; Breton-Gorius J; Delmas PD; Kaplan C
J Bone Miner Res; 1991 Oct; 6(10):1059-70. PubMed ID: 1796754
[TBL] [Abstract][Full Text] [Related]
11. CD36 peptides enhance or inhibit CD36-thrombospondin binding. A two-step process of ligand-receptor interaction.
Leung LL; Li WX; McGregor JL; Albrecht G; Howard RJ
J Biol Chem; 1992 Sep; 267(25):18244-50. PubMed ID: 1381367
[TBL] [Abstract][Full Text] [Related]
12. Thrombospondin promotes platelet aggregation.
Tuszynski GP; Rothman VL; Murphy A; Siegler K; Knudsen KA
Blood; 1988 Jul; 72(1):109-15. PubMed ID: 3390605
[TBL] [Abstract][Full Text] [Related]
13. Characterization of an anti-thrombospondin monoclonal antibody (P8) that inhibits human blood platelet functions. Normal binding of P8 to thrombin-activated Glanzmann thrombasthenic platelets.
Boukerche H; McGregor JL
Eur J Biochem; 1988 Jan; 171(1-2):383-92. PubMed ID: 3338471
[TBL] [Abstract][Full Text] [Related]
14. Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interaction.
Clezardin P; Serre CM; Trzeciak MC; Drouin J; Delmas PD
Cancer Res; 1991 May; 51(10):2621-7. PubMed ID: 1708697
[TBL] [Abstract][Full Text] [Related]
15. Expression and initial characterization of a recombinant human thrombospondin heparin binding domain.
Yabkowitz R; Lowe JB; Dixit VM
J Biol Chem; 1989 Jun; 264(18):10888-96. PubMed ID: 2659597
[TBL] [Abstract][Full Text] [Related]
16. Biological activities of peptides and peptide analogues derived from common sequences present in thrombospondin, properdin, and malarial proteins.
Tuszynski GP; Rothman VL; Deutch AH; Hamilton BK; Eyal J
J Cell Biol; 1992 Jan; 116(1):209-17. PubMed ID: 1730745
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
[TBL] [Abstract][Full Text] [Related]
18. Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1.
Voland C; Serre CM; Delmas P; Clézardin P
J Bone Miner Res; 2000 Feb; 15(2):361-8. PubMed ID: 10703939
[TBL] [Abstract][Full Text] [Related]
19. Functional involvement of thrombospondin in platelet aggregation induced by low versus high concentrations of thrombin.
Kao KJ; Shaut DM; Klein PA
Thromb Haemost; 1986 Feb; 55(1):136-42. PubMed ID: 3705001
[TBL] [Abstract][Full Text] [Related]
20. Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood.
Maugeri N; Di Fabio G; Barbanti M; de Gaetano G; Donati MB; Cerletti C
Thromb Haemost; 2007 Jun; 97(6):965-73. PubMed ID: 17549299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
